Please assess the completion status of the following clinical trial:

Trial Title: A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COPD diagnosis~* At least 10 pack year smoking history~* Post-albuterol FEV1 greater than or equal to 40% to less than or equal to 80% of predicted normal~* An FEV1/FVC ratio of less than or equal to 0.70~Exclusion Criteria:~* Current diagnosis of asthma~* Other respiratory disorder other than COPD~* Abnormal and clinical significant ECG~* Chest x-ray clinically significant abnormality not believed to be due to COPD~* Body Mass Index of greater than or equal to 40/kg/m2~* Use of Long Term Oxygen Therapy~* Lung resection surgery~* Women pregnant or lactating at Visit 1~* Previously diagnosed cancer unless in complete remission for 2 years at Visit 1

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler (Type: EXPERIMENTAL): Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD
- SPIRIVA® HANDIHALER® inhaler (Type: ACTIVE_COMPARATOR): Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID

Based on this trial design, predict the completion outcome and termination type (if applicable).